Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Oral Rapamycin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    51 result(s) found for: Oral Rapamycin. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2020-003231-19 Sponsor Protocol Number: ViRap Start Date*: Information not available in EudraCT
    Sponsor Name:The Children's Memorial Health Institute
    Full Title: Randomized, placebo-controlled, double-blind and double-dummy clinical trial comparing the safety, tolerability, and efficacy of vigabatrin and rapamycin in a preventive treatment of infants with T...
    Medical condition: Tuberous Sclerosis Complex Epilepsy Tumors associated with Tuberous Sclerosis Complex
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-004548-64 Sponsor Protocol Number: RaRETS Start Date*: Information not available in EudraCT
    Sponsor Name:The Children's Memorial Health Institute
    Full Title: Multicenter, randomized, double-blind, placebo controlled study to assess the efficacy and safety of Rapamycin in drug Resistant Epilepsy associated with TSC (RaRE-TS)
    Medical condition: tuberous sclerosis complex, epilepsy, organ tumors associated with tuberous sclerosis
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-022655-29 Sponsor Protocol Number: RATE-trial Start Date*: 2011-05-30
    Sponsor Name:Erasmus MC
    Full Title: Randomised open label cross-over study into the efficacy of RApamycin in children with Tuberous sclerosis complex with intractable Epilepsy (RATE-trial)
    Medical condition: Epilepsy in children with Tuberous Sclerosis Complex
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012740-17 Sponsor Protocol Number: 28245 Start Date*: 2009-07-30
    Sponsor Name:MUMC
    Full Title: Topical rapamycin to treat fibrofolliculomas in Birt-Hogg-Dubé syndrome.
    Medical condition: Facial fibrofolliculomas in Birt-Hogg-Dubé syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002399-28 Sponsor Protocol Number: RAP-ALS Start Date*: 2017-07-14
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO DI MODENA
    Full Title: Rapamycin (Sirolimus) treatment for amyotrophic lateral sclerosis
    Medical condition: definite or probable ALS
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006702-78 Sponsor Protocol Number: BraimTOR-NEURO Start Date*: Information not available in EudraCT
    Sponsor Name:The Children's Memorial Health Institute
    Full Title: Open, randomized, IInd phase clinical study evaluating the safety and efficacy of rapamycin in the treatment of drug-resistant epilepsy in children with rare and ultra-rare diseases of the central ...
    Medical condition: epilepsy, mTORopathies, focal cortical dysplasia, LEATS
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006689-18 Sponsor Protocol Number: BraimTOR-ONKO Start Date*: Information not available in EudraCT
    Sponsor Name:The Children's Memorial Health Institute
    Full Title: An open randomized phase II clinical trial evaluating the safety and efficacy of rapamycin in the treatment of gliomas high-grade malignant gliomas in children as part of the establishment manageme...
    Medical condition: high grade glioma
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-006308-12 Sponsor Protocol Number: TSP-RAP-1 Start Date*: 2012-07-16
    Sponsor Name:Fundación Investigación Hospital Ramón y Cajal
    Full Title: phase II clinical trial, to study the efficacy and safety of topical rapamycin in reducing facial angiofibromas.
    Medical condition: Facial tumors (angiofibromas) associated with tuberous sclerosis complex.
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000702-29 Sponsor Protocol Number: LORALAM-2020 Start Date*: 2021-06-07
    Sponsor Name:IDIBELL (Institut d’Investigació Biomédica de Bellvitge)
    Full Title: Phase-II randomized clinical trial to evaluate the effect of Loratadine associated with Rapamune on Lymphagioleiomyomatosis (LAM).
    Medical condition: EFFECT OF LORATADINE ON LYMPHANGIOLEIOMYOMATOSIS
    Disease: Version SOC Term Classification Code Term Level
    21.0 10038738 - Respiratory, thoracic and mediastinal disorders 10049459 Lymphangioleiomyomatosis PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022589-29 Sponsor Protocol Number: EP-TSC-624 Start Date*: 2011-03-22
    Sponsor Name:University of Oxford
    Full Title: Investigation of pathways regulating cell survival and early antiangiogenic response to single agent Everolimus or Rapamycin in renal cancer
    Medical condition: Renal cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038389 Renal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-007177-20 Sponsor Protocol Number: Sirolimus_Liver_Tolerance Start Date*: 2009-09-07
    Sponsor Name:Hospital Clinic Barcelona
    Full Title: EFECTO DEL SIROLIMUS SOBRE LOS BIOMARCADORES RELACIONADOS CON LA TOLERANCIA EN RECEPTORES DE TRASPLANTE HEPÁTICO ESTABLES
    Medical condition: Stable liver transplant recipients identified as non-tolerant (i.e. requiring indefinite immunosuppressive therapy) on the basis of peripheral blood transcriptional biomarkers.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10024716 Liver transplantation LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-006557-25 Sponsor Protocol Number: RAPYD-STUDY Start Date*: 2007-12-20
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE
    Full Title: RAPAMYCIN FOR TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
    Medical condition: ADPKD type I
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038359 Renal and urinary disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000363-10 Sponsor Protocol Number: 0468H1-101497 Start Date*: 2004-11-08
    Sponsor Name:Wyeth Pharmaceuticals
    Full Title: A Randomized Open Label Study to compare the Safety and Efficacy of Two Different Sirolimus Regimens with a Tacrolimus + Mycophenolate Mofetil Regimen in de novo Renal Allograft Recipients
    Medical condition: de novo Renal Allograft Recipients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-001106-26 Sponsor Protocol Number: EC11-444-OSTEOSARC Start Date*: 2012-07-02
    Sponsor Name:JAVIER MARTÍN BROTO
    Full Title: PHASE II MULTICENTRIC AND PROSPECTIVE TRIAL WITH GEMCITABINE AND RAPAMYCIN IN SECOND LINE OF METASTATIC OSTEOSARCOMA
    Medical condition: Patients diagnosed with metastatic osteosarcoma cancer types that have been treated with chemotherapy and have active disease that permits to receive this treatment combination.
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004062-15 Sponsor Protocol Number: RIST-rNB-2011 Start Date*: 2012-08-06
    Sponsor Name:University Hospital of Regensburg
    Full Title: Prospective, open label, randomized phase II trial to assess a multimodal molecular targeted therapy in children, adolescent and young adults with relapsed or refractory high risk neuroblastoma
    Medical condition: Relapsed or refractory high risk neuroblastoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002823-15 Sponsor Protocol Number: 1968 Start Date*: 2005-10-25
    Sponsor Name:Nottingham University Hospitals NHS Trust
    Full Title: A PHASE I/II TRIAL OF THE USE OF SIROLIMUS (RAPAMUNE) AND LOW DOSE ARA-C IN OLDER PATIENTS WITH ACUTE MYELOID LEUKAEMIA (AML)
    Medical condition: Acute myeloid leukaemia (AML) and high risk myelodysplasia (MDS)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-000656-33 Sponsor Protocol Number: 507088 Start Date*: 2005-06-06
    Sponsor Name:Royal Devon and Exeter NHS Foundation Trust
    Full Title: A Phase I/II Study of Sirolimus (Rapamune TM) in Combination with Cyclophosphamide and Dexamethasone in Relapsed Myeloma
    Medical condition: Plasma Cell Myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000973-69 Sponsor Protocol Number: 0468H1-318-WW Start Date*: 2005-04-21
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc
    Full Title: A Randomized, Open-Label, Comparative Evaluation of the Safety and Efficacy of Sirolimus versus Cyclosporine when Combined in a Regimen Containing Basiliximab, Mycophenolate Mofetil, and Corticoste...
    Medical condition: The rationale for the present study is to assess whether a CNI-free regimen including antibody induction, sirolimus, and mycophenolate mofetil (MMF) results in improved long-term renal function wit...
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SE (Prematurely Ended) AT (Completed) GB (Completed) CZ (Prematurely Ended) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000935-27 Sponsor Protocol Number: 0468H1-313-EU Start Date*: 2005-06-15
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc.Clinical Research & Development Department
    Full Title: A Randomized, Open-label, Comparative Evaluation of Conversion from Calcineurin Inhibitor Treatment to Sirolimus Treatment Versus Continued Calcineurin Inhibitor Treatment in Liver Allograft Recipi...
    Medical condition: Liver allograft recipients under maintenance therapy
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2023-000127-36 Sponsor Protocol Number: KIH22001 Start Date*: 2023-04-04
    Sponsor Name:Karolinska Institutet
    Full Title: Evaluating rapamycin treatment in Alzheimer’s disease using positron emission tomography (ERAP)
    Medical condition: Alzheimer's disease (AD) and mild cognitive impairment (MCI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001897 Alzheimer's disease (incl subtypes) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 07:10:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA